Analysed SANA BIOTECHNOLOGY INC (SANA:NASDAQ) News Sources
Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment
23-04-2026
yahoo.com
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes
27-04-2026
yahoo.com
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
27-04-2026
yahoo.com
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
05-05-2026
yahoo.com
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
11-05-2026
yahoo.com
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
12-05-2026
yahoo.com
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
15-05-2026
yahoo.com
What is the current price of SANA BIOTECHNOLOGY INC (SANA:NASDAQ)?
The current price of SANA BIOTECHNOLOGY INC (SANA:NASDAQ) is $3.13.
SANA BIOTECHNOLOGY INC (SANA:NASDAQ) absolute price change since previous trading day?
The absolute price change of SANA BIOTECHNOLOGY INC (SANA:NASDAQ) since the previous trading day is $-0.08.
SANA BIOTECHNOLOGY INC (SANA:NASDAQ) percentage price change since previous trading day?
The percentage price change of SANA BIOTECHNOLOGY INC (SANA:NASDAQ) since the previous trading day is -2.4922%.
What is the most recent average sentiment score for SANA BIOTECHNOLOGY INC (SANA:NASDAQ)?
The most recent average sentiment score for SANA BIOTECHNOLOGY INC (SANA:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for SANA BIOTECHNOLOGY INC (SANA:NASDAQ)?
The most recent sentiment for SANA BIOTECHNOLOGY INC (SANA:NASDAQ) is .
SEC-8K** Filing Available For SANA BIOTECHNOLOGY INC (SANA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.